Stock comparison
Amneal Pharmaceuticals
IDEXX Laboratories
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
AMRX
Amneal Pharmaceuticals
Market cap
$3.96B
Sector
Healthcare
IDXX
IDEXX Laboratories
Market cap
$44.12B
Sector
Healthcare
Overall winner
IDEXX Laboratories IDXX
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | AMRX | IDXX | Winner |
|---|---|---|---|
| Warren Buffett | 54C | 75B | IDXX |
| Benjamin Graham | 57D | 80A | IDXX |
| Philip Fisher | 63C | 75B | IDXX |
| Peter Lynch | 54C | 71B | IDXX |
| Joel Greenblatt | 31F | 83C | IDXX |
| Charlie Munger | 53D | 87A | IDXX |
| Terry Smith | 42D | 84A | IDXX |
Side-by-side metrics
| Metric | AMRX | IDXX |
|---|---|---|
| Market cap | $3.96B | $44.12B |
| P/E (TTM) | 32.1x | 39.0x |
| EV/EBIT | 14.9x | 31.6x |
| ROIC (TTM) | 12.64% | 40.66% |
| Gross margin | 38.66% | 62.05% |
| Net margin | 4.02% | 24.63% |
| Revenue CAGR 5y | 9.58% | 7.56% |
| EPS CAGR 5y | 34.63% | 10.79% |
| Debt / Equity | - | 0.7x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
AMRX leads on
- Debt / Equity-vs 0.7x+101%
- EPS CAGR 5y34.63%vs 10.79%+69%
- EV/EBIT14.9xvs 31.6x+53%
- Revenue CAGR 5y9.58%vs 7.56%+21%
IDXX leads on
- Market cap$44.12Bvs $3.96B+91%
- Net margin24.63%vs 4.02%+84%
- ROIC (TTM)40.66%vs 12.64%+69%
- Gross margin62.05%vs 38.66%+38%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.